Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CSL To Include Seizure Warning On 2012 Version Of Fluvax Vaccine

This article was originally published in PharmAsia News

Executive Summary

Australia’s CSL has added a warning to its label on next year’s Fluvax influenza vaccine to advise of a possibility of serious side effects in children, an advisory not included on this year’s version.

You may also be interested in...

Aurobindo’s AuroLife Warned By FDA Over Leaky Facilities

After issuing Form 483 observations, the FDA has issued a warning letter to Aurobindo’s AuroLife linked to its manufacturing facility in New Jersey. The agency has warned that if the violations are not corrected promptly, it will take further action to ensure quality control.

EU Plans IP Law Shake-Up

European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by the European pharmaceutical industry federation EFPIA. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.

AZ Will Sideline ‘Lucky Mistake’ To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts